Taken together our data highlight that CD33+AML adoptive immunotherapy using CD33-specific EBV-CTLs might be an alternative strategy to an antibody-based therapy such as gemtuzumab ozogamicin. The gene discussed is CD33; the disease is acute myeloid leukemia.